B
TBPH icon

Barings’s Theravance Biopharma TBPH Stock Holding History

Barings’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-11,800
Closed -$404K – 982
2017
Q3 		$404K Hold
11,800
– – 0.01% 693
2017
Q2 		$470K Sell
11,800
-11,800
-50% -$454K 0.01% 634
2017
Q1 		$868K Buy
23,600
+11,800
+100% +$377K 0.01% 804
2016
Q4 		$376K Hold
11,800
– – 0.01% 710
2016
Q3 		$428K Buy
+11,800
New +$329K 0.01% 612

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Barings's TBPH Position: Q4 2017 in Review

Barings sold out of Theravance Biopharma (TBPH) in Q4 2017, closing a stake of 11,800 shares — an estimated $404K sold.

Barings first reported a position in TBPH in Q3 2016 and held it in 5 quarters. The position peaked at $868K in Q1 2017. 84 funds tracked by Wall St. Rank hold TBPH as of Q4 2017.

  • Barings reported no remaining Theravance Biopharma position as of Q4 2017 after selling out during the quarter.
  • Barings sold 11,800 Theravance Biopharma shares in Q4 2017, an estimated $404K.
  • Barings first reported a position in Theravance Biopharma in Q3 2016 and held it in 5 quarters.
  • Barings's Theravance Biopharma position peaked at $868K in Q1 2017.
  • 84 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2017.

Based on Barings's 13F filing for Q4 2017, filed 8 Feb 2018.